Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 150 of 672 entries
View as:

Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function

Phase: N/A Priority: Normal
NCT ID: NCT02808312 Org: User:
Start: 07/13/16 End: 10/16/18 Due: 10/16/19

Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)

Phase: N/A Priority: Normal
NCT ID: NCT02345252 Org: User:
Start: 01/26/15 End: 01/09/19 Due: 01/09/20

Study of Magrolimab Combinations in Participants With Myeloid Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT04778410 Org: User:
Start: 06/28/21 End: 03/04/24 Due: 03/04/25

Phase Ib Study of SC Milatuzumab in SLE

Phase: N/A Priority: Normal
NCT ID: NCT01845740 Org: User:
Start: 01/31/07 End: 06/30/09 Due: 06/30/10

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01803282 Org: User:
Start: 03/29/13 End: 04/23/19 Due: 04/23/20

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

Phase: N/A Priority: Normal
NCT ID: NCT01475838 Org: User:
Start: 11/30/11 End: 12/31/14 Due: 12/31/15

Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3

Phase: N/A Priority: Normal
NCT ID: NCT01260350 Org: User:
Start: 12/31/10 End: 12/31/13 Due: 12/31/14

The Safety of Tenofovir Disoproxil Fumarate Taken With Other Anti-HIV Drugs to Treat HIV-Infected Patients

Phase: N/A Priority: Normal
NCT ID: NCT00007436 Org: User:
Start: - End: - Due: -

Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)

Phase: N/A Priority: Normal
NCT ID: NCT04313881 Org: User:
Start: 09/09/20 End: 09/13/23 Due: 09/13/24

Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents

Phase: N/A Priority: Normal
NCT ID: NCT02276612 Org: User:
Start: 12/03/14 End: 10/23/17 Due: 10/23/18

A Phase I/II Study of the Safety, Tolerance, and Pharmacokinetics of 9-(2-Phosphonylmethoxyethyl)Adenine ( PMEA; Adefovir ) in Patients With Advanced HIV Disease.

Phase: N/A Priority: Normal
NCT ID: NCT00002115 Org: User:
Start: - End: - Due: -

Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)

Phase: N/A Priority: Normal
NCT ID: NCT06562907 Org: User:
Start: 08/28/24 End: 07/31/26 Due: 07/31/27

ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial

Phase: N/A Priority: Normal
NCT ID: NCT00772902 Org: User:
Start: 10/31/08 End: 10/31/09 Due: 10/31/10

Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection

Phase: N/A Priority: Normal
NCT ID: NCT02378961 Org: User:
Start: 02/16/15 End: 01/26/16 Due: 01/26/17

Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)

Phase: N/A Priority: Normal
NCT ID: NCT03987074 Org: User:
Start: 07/29/19 End: 07/13/20 Due: 07/13/21

Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Phase: N/A Priority: Normal
NCT ID: NCT02397694 Org: User:
Start: 03/23/15 End: 02/27/19 Due: 02/27/20

Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02953782 Org: User:
Start: 11/02/16 End: 02/10/20 Due: 02/10/21

Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)

Phase: N/A Priority: Normal
NCT ID: NCT04323761 Org: User:
Start: - End: - Due: -

Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)/TDF, and Entecavir (ETV) in the Treatment of Chronic HBV in Subjects With Decompensated Liver Disease.

Phase: N/A Priority: Normal
NCT ID: NCT00298363 Org: User:
Start: 04/30/06 End: 04/30/11 Due: 04/30/12

Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF)

Phase: N/A Priority: Normal
NCT ID: NCT04009057 Org: User:
Start: 07/09/19 End: 03/21/22 Due: 03/21/23

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02862535 Org: User:
Start: 09/20/16 End: 10/25/19 Due: 10/25/20

A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function

Phase: N/A Priority: Normal
NCT ID: NCT05760300 Org: User:
Start: 03/15/23 End: 07/23/24 Due: 07/23/25

An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS

Phase: N/A Priority: Normal
NCT ID: NCT00002142 Org: User:
Start: - End: - Due: -

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen

Phase: N/A Priority: Normal
NCT ID: NCT02536313 Org: User:
Start: 07/29/15 End: 06/28/16 Due: 06/28/17

Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT02538614 Org: User:
Start: 12/29/15 End: 07/05/17 Due: 07/05/18